Amgen (AMGN) Deferred Taxes (2013 - 2026)
Amgen (AMGN) recorded quarterly Deferred Taxes of -$176.0 million in Q1 2026, down 826.32% quarter-over-quarter from -$19.0 million in Q4 2025, and up 29.6% on a YoY basis from -$135.8 million in Q1 2025.
Amgen (AMGN) Deferred Taxes (2013 - 2026) Analysis & Trends
Amgen's Deferred Taxes history runs 14 years deep, the most recent figure standing at -$176.0 million for Q1 2026.
- In Q1 2026, Deferred Taxes rose 29.6% year-over-year to -$176.0 million; the TTM figure through Mar 2026 stood at -$647.0 million (up 39.93% YoY), while the FY2025 annual figure was -$721.0 million, up 41.29% from the prior year.
- Deferred Taxes was -$176.0 million for Q1 2026 at Amgen, down from -$19.0 million in the prior quarter.
- In the past five years, Deferred Taxes ranged from a high of -$19.0 million in Q4 2025 to a low of -$623.0 million in Q4 2023.
- Historically, Deferred Taxes has averaged -$270.4 million across 5 years, with a median of -$263.0 million in 2022.
- The sharpest annual moves came in 2024 and 2025: Deferred Taxes tumbled 718.37% in 2024, then surged 94.31% in 2025.
- A 5-year view of Deferred Taxes shows it stood at -$351.0 million in 2022, then tumbled by 77.49% to -$623.0 million in 2023, then jumped by 46.39% to -$334.0 million in 2024, then soared by 94.31% to -$19.0 million in 2025, then plunged by 826.32% to -$176.0 million in 2026.
- The last three Deferred Taxes figures came in at -$176.0 million (Q1 2026), -$19.0 million (Q4 2025), and -$30.0 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Deferred Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn | - |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn | 1.48 Bn |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn | 159.00 Mn |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn | 137.00 Mn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn | -315.00 Mn |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn | -176.00 Mn |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn | 179.00 Mn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn | -12.00 Mn |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn | 161.00 Mn |
| 10 | Novartis Ag | 109.78 Bn | 109.09 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -176.00 Mn |
| Dec 31, 2025 | -19.00 Mn |
| Sep 30, 2025 | -30.00 Mn |
| Jun 30, 2025 | -422.00 Mn |
| Mar 31, 2025 | -250.00 Mn |
| Dec 31, 2024 | -334.00 Mn |
| Sep 30, 2024 | -110.00 Mn |
| Jun 30, 2024 | -383.00 Mn |
| Mar 31, 2024 | -401.00 Mn |
| Dec 31, 2023 | -623.00 Mn |
| Sep 30, 2023 | -447.00 Mn |
| Jun 30, 2023 | -154.00 Mn |
| Mar 31, 2023 | -49.00 Mn |
| Dec 31, 2022 | -351.00 Mn |
| Sep 30, 2022 | -333.00 Mn |
| Jun 30, 2022 | -263.00 Mn |
| Mar 31, 2022 | -251.00 Mn |
| Dec 31, 2021 | -189.00 Mn |
| Sep 30, 2021 | -127.00 Mn |
| Jun 30, 2021 | -46.00 Mn |